CSPC Pharma Presents Data from Cervical Cancer Study at Gynecologic Cancer Society Meeting
MT Newswires Live
Oct 08
CSPC Pharmaceutical Group (HKG:1093) presented data from a phase I clinical study of SYS6002 as a rapid oral presentation at the 2026 Annual Global Meeting of the International Gynecologic Cancer Society.
The trial testing the drug as monotherapy for the treatment of advanced cervical cancer found it to have a manageable safety profile and preliminary efficacy, a Thursday bourse filing showed.
The drug is currently being studied for the treatment of advanced cervical cancer previously treated with immunotherapy in a phase III trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.